Back to search results

Ubamatamab for SMARCB1-Deficient Cancers

This study is testing ubamatamab, either alone or with cemiplimab, for people with advanced SMARCB1-deficient cancers like renal medullary carcinoma (RMC) or epithelioid sarcoma (ES). These are cancers where a specific protein called SMARCB1 is missing. You may be able to join if your cancer has progressed after at least one previous treatment. The main goal is to see how safe these treatments are and if they cause side effects. Researchers will also look at how many people respond to the treatment and how long the disease is controlled. The study plans to enroll 40 participants, but its current status is unclear.

Study design
This is an interventional study planning to enroll 40 participants. It is testing ubamatamab alone or in combination with cemiplimab.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Safety and side effects will be measured throughout the study, which is expected to last an average of 1 year.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06444880

Phase II Trial of Ubamatamab Alone or in Combination With Cemiplimab in MUC16-Expressing SMARCB1-Deficient Malignancies

Active, Not Recruiting
PHASE2Ages 12+InterventionalTreatment
M.D. Anderson Cancer Center
~15 participants
Updated 2026-08-06 on ClinicalTrials.gov
What's tested:UbamatamabCemiplimab

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Safety and adverse events (AEs)
Measured over Through study completion; an average of 1 year.

Conditions

SMARCB1-Deficient Malignancies
Epithelioid Sarcoma
Renal Medullary Carcinoma

Explore related trials

Epithelioid SarcomaKidney Medullary CarcinomaSMARCB1-Deficient MalignanciesSWI/SNF-Related Matrix-Associated Actin-Dependent Regulator of Chromatin Subfamily B Member 1

Where it's being run

1 sites across 1 states
Texas1

Study leadership

  • Pavlos Msaouel, MD,PHD,PHD · PRINCIPAL_INVESTIGATOR · M.D. Anderson Cancer Center

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Postmenopausal (no menses in greater than or equal to 12 consecutive months).
History of hysterectomy or bilateral salpingo-oophorectomy.
Ovarian failure (Follicle Stimulating Hormone and Estradiol in menopausal range, who have received Whole Pelvic Radiation Therapy).
History of bilateral tubal ligation or another surgical sterilization procedure. 15. Ability to understand and the willingness to sign a written informed consent document.

What this trial measures

  • Safety and adverse events (AEs)Through study completion; an average of 1 year.

    Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0